FCA
AMPH icon

FinTrust Capital Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

FinTrust Capital Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,000
Closed -$196K – 1186
2022
Q3 		$196K Buy
7,000
+3,000
+75% +$98K 0.05% 272
2022
Q2 		$139K Hold
4,000
– – 0.03% 321
2022
Q1 		$143K Buy
+4,000
New +$113K 0.03% 349

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

FinTrust Capital Advisors's AMPH Position: Q4 2022 in Review

FinTrust Capital Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2022, closing a stake of 7,000 shares — an estimated $196K sold.

FinTrust Capital Advisors first reported a position in AMPH in Q1 2022 and held it in 3 quarters. The position peaked at $196K in Q3 2022. 211 funds tracked by Wall St. Rank hold AMPH as of Q4 2022.

  • FinTrust Capital Advisors reported no remaining Amphastar Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • FinTrust Capital Advisors sold 7,000 Amphastar Pharmaceuticals shares in Q4 2022, an estimated $196K.
  • FinTrust Capital Advisors first reported a position in Amphastar Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • FinTrust Capital Advisors's Amphastar Pharmaceuticals position peaked at $196K in Q3 2022.
  • 211 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2022.

Based on FinTrust Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.